Skip to main content
Clinical Trials/NCT06151379
NCT06151379CompletedNot Applicable

The Relation Between the Initial Value of the Skeletal Mass Index and Pathological Response

Acıbadem Atunizade Hospital1 site in 1 country69 target enrollmentStarted: March 1, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
69
Locations
1
Primary Endpoint
Sarcopenic index

Study Overview

Brief Summary

The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Detailed Description

In patients with operable breast cancer (BC) receiving neoadjuvant chemotherapy (NAC), the pathological response rate was found to be related to body composition. The success of complete pathologic response (pCR) is a known prognostic factor in BC patients treated with NAC. The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Retrospective

Eligibility Criteria

Ages
29 Years to 72 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Early and locally advanced operated breast cancer patients receiving neoadjuvant chemotherapy.

Exclusion Criteria

  • Patients who did not receive neoadjuvant chemotherapy, had metastatic breast cancer and whose radiological images were not available.

Outcomes

Primary Outcomes

Sarcopenic index

Time Frame: Through study completion, an average of 1 year.

skeletal muscle area (cm2)/height (m2) et L3 level

Secondary Outcomes

  • Body mass index(Through study completion, an average of 1 year.)

Investigators

Sponsor
Acıbadem Atunizade Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ebru Yilmaz

Principal Investigator

Acıbadem Atunizade Hospital

Study Sites (1)

Loading locations...

Similar Trials

Muscle Parameters and Pathological... | Clinical Trial